Novartis and Qualcomm Ventures punt $100 million on early stage companies

Subscribe via: RSS

Big pharma, Financing, Partnering, Pharma

Novartis and Qualcomm Ventures punt $100 million on early stage companies

Posted on 14 January 2015

Tags: big pharma, financing, Novartis, partnering

Novartis Pharmaceuticals announced the establishment of a joint investment company with Qualcomm Ventures to target early stage companies who offer technologies, products or services that "go beyond the pill" to benefit physicians and patients.

Novartis establishing a joint investment company with Qualcomm Ventures of up to USD 100 million to support early stage companies with technologies, products or services that "go beyond the pill".

Searching for more deal information? Current Partnering offers the following options:

CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

Digital technologies can optimize the value of innovative medicines by providing integrated solutions for physicians and patients and changing the practice of medicine.

Qualcomm Ventures, the venture investment group of Qualcomm Incorporated, is a leading global investor in wireless technologies and one of the most active strategic investors in digital health.

For further deal information visit Current Agreements (subscription required)

View: Top pharmaceutical companies

View: Top biotech companies

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends